Wuhan Hiteck Biological Pharma Co., Ltd (SHE: 300683), a Chinese biopharmaceutical company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its drug Aponermin. This approval is for the treatment of adult patients with recurrent or refractory multiple myeloma who have previously undergone at least two systemic treatment regimens, including thalidomide plus dexamethasone. Aponermin, also known as circularly permuted TRAIL (CPT), is a recombinant mutant of human Apo2L/TRAIL and is developed as a targeted therapy for multiple myeloma and other hematologic malignancies.
Aponermin’s Mechanism of Action
Aponermin functions as a dual pro-apoptotic receptor agonist, directly activating both pro-apoptotic receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5). This mechanism makes it a potentially effective treatment for patients with multiple myeloma, a cancer that forms in plasma cells and is characterized by its resistance to traditional therapies.
Significance of the Approval
The NMPA’s approval of Aponermin marks a significant advancement in the treatment options available for patients with recurrent or refractory multiple myeloma in China. It offers a new approach to treatment, specifically targeting the malignancy at the cellular level and providing an alternative for patients who have not responded to standard therapies.-Fineline Info & Tech
